Treatment of Acinetobacter spp infections

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Acinetobacter spp. are significant nosocomial pathogens.
• Antimicrobial resistance, including to beta-lactams, aminoglycosides, and quinolones, is a major challenge.
• Imipenem, a common treatment, is not effective against all Acinetobacter isolates, necessitating alternative therapies.

Purpose of the Study:

• To review current and emerging therapeutic options for Acinetobacter spp. infections.
• To evaluate the efficacy of various antimicrobial agents and combinations against Acinetobacter.
• To identify potential treatments for multi-drug resistant Acinetobacter infections.

Main Methods:

• In vitro studies assessing antimicrobial activity and synergy.
• Experimental infection models in mice and rabbits.
• Review of retrospective comparative studies and uncontrolled clinical studies.

Main Results:

• In vitro studies show activity for beta-lactamase inhibitors, polymyxins, doxycycline, and rifampin.
• Rifampin and doxycycline demonstrated efficacy in experimental models.
• Ampicillin-sulbactam may be comparable to imipenem for pneumonia and bacteremia; ampicillin-sulbactam and colistin show potential for multi-resistant infections in uncontrolled studies.

Conclusions:

• Effective treatment options for Acinetobacter infections are limited due to resistance.
• Several agents including ampicillin-sulbactam, doxycycline, and rifampin show promise.
• Further research, including randomized controlled trials, is needed to establish optimal treatment strategies.